Fambrini M, Penna C, Fallani M G, Pieralli A, Mattei A, Scarselli G, Taddei G L, Marchionni M
Department of Gynecology, Perinatology and Human Reproduction, School of Medicine, University of Florence, Via Morgagni 85, 50134 Florence, Italy.
Int J Gynecol Cancer. 2007 Jan-Feb;17(1):127-31. doi: 10.1111/j.1525-1438.2007.00802.x.
The purpose of this study is to evaluate the feasibility, safety, and potential therapeutic benefit of laser CO(2) conization of the cervix for in situ and minimally invasive carcinoma diagnosed during pregnancy. Twenty-six pregnant patients with biopsy-proven carcinoma in situ/cervical intraepithelial neoplasia III but colposcopically suspicious for invasion underwent laser CO(2) conization during the 18th week of gestation in an outpatient setting under local anesthesia. No major intraoperative or postoperative complications occurred, and cervical cerclage was not required in any case. Two cases (7.7%) of occult FIGO stage IA1 minimally invasive cervical cancers with free surgical margins were diagnosed. Both patients delivered vaginally at term and were free of disease at postpartum follow-up. Median length of gestation was 39.1 weeks with a median birth weight of 3450 g. All 1-min Apgar scores were 8 or greater. Twenty patients (76.9%) delivered vaginally, while six patients underwent cesarean section for indications not related to the prior conization. After a mean postpartum follow-up of 18 months (range 3-42), 92.3% of patients continued to have both cytologic and colposcopic evaluations negative for persistent or recurrent disease. Two cases of persistent intraepithelial disease were successfully managed by reconization. In summary, our data suggest that laser CO(2) conization performed within the 18th week of gestation is safe for both the patient and the fetus, provides reliable histologic diagnosis, and can be curative. Further studies are required to confirm the favorable risk-benefit ratio of laser CO(2) conization in the management of non-reassuring cervical lesions observed in the first half of pregnancy.
本研究的目的是评估激光二氧化碳宫颈锥切术对妊娠期诊断为原位癌和微浸润癌的可行性、安全性及潜在治疗益处。26例经活检证实为原位癌/宫颈上皮内瘤变III级但阴道镜检查怀疑有浸润的孕妇,于妊娠第18周在门诊局部麻醉下接受了激光二氧化碳宫颈锥切术。未发生重大术中或术后并发症,且无一例需要宫颈环扎。诊断出2例(7.7%)隐匿性FIGO IA1期微浸润宫颈癌,手术切缘阴性。两名患者均足月阴道分娩,产后随访无疾病复发。妊娠中位数为39.1周,出生体重中位数为3450g。所有新生儿1分钟阿氏评分均为8分或更高。20例(76.9%)患者阴道分娩,6例因与先前锥切术无关的指征行剖宫产。产后平均随访18个月(范围3 - 42个月),92.3%的患者细胞学和阴道镜检查均未发现持续性或复发性疾病。2例持续性上皮内疾病经再次锥切成功治疗。总之,我们的数据表明,在妊娠第18周内行激光二氧化碳宫颈锥切术对患者和胎儿均安全,能提供可靠的组织学诊断,且可治愈疾病。需要进一步研究以证实激光二氧化碳宫颈锥切术在处理妊娠前半期发现的可疑宫颈病变时的良好风险效益比。